Profile data is unavailable for this security.
About the company
Altamira Therapeutics Ltd. is a Bermuda-based company engaged in developing ribonucleic acid (RNA)-based therapeutics for extrahepatic targets (OligoPhore/SemaPhore delivery platforms). The Company has two flagship short interfering (siRNA) programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The delivery platform is also suited for messenger RNA (mRNA) and other types of RNA therapeutics and is focused to be leveraged via out-licensing to pharma or biotech companies. The therapeutic objective for AM-401 is to slow down KRAS driven tumor cell growth and proliferation or to stop it altogether by delivering siRNA specifically inside tumor cells for gene knock down. AM-411 is a polyplex nanoparticle delivering siRNA to inflamed tissues to target the NF-kB signaling pathway, a critical regulator of immune and inflammatory responses. Like AM-401, the drug product is based on its OligoPhore technology.
- Revenue in USD (TTM)0.00
- Net income in USD-8.00m
- Incorporated2019
- Employees10.00
- LocationAltamira Therapeutics LtdClarendon House, 2 Church StreetHAMILTON 6300BermudaBMU
- Phone+41 612011350
- Websitehttps://aurismedical.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revelation Biosciences Inc | 0.00 | -8.96m | 3.30m | 9.00 | -- | 0.3482 | -- | -- | -32.09 | -32.09 | 0.00 | 5.80 | 0.00 | -- | -- | 0.00 | -54.61 | -- | -91.95 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 98.89 | -- | -- | -- |
| Aditxt Inc | 645.19k | -32.70m | 3.35m | 47.00 | -- | 0.1651 | -- | 5.19 | -153.12 | -153.12 | 2.14 | 12.17 | 0.0233 | 0.8927 | 1.38 | 13,727.45 | -117.12 | -192.78 | -251.19 | -321.59 | -17.30 | -- | -5,020.30 | -7,208.65 | 0.2382 | -4.09 | 0.5020 | -- | -30.90 | -- | -18.11 | -- | -- | -- |
| Cyclacel Pharmaceuticals Inc | 420.00k | -22.76m | 3.35m | 12.00 | -- | 3.99 | -- | 7.98 | -26.72 | -26.72 | 0.4924 | 0.5732 | 0.0228 | -- | 0.1106 | -- | -122.40 | -57.58 | -212.95 | -69.81 | -- | -- | -5,370.24 | -18,789.29 | -- | -170.83 | 0.00 | -- | -- | 22.87 | -6.34 | -- | -31.23 | -- |
| Manuka Inc | 671.00k | -1.14m | 3.36m | 4.00 | -- | -- | -- | 5.01 | -0.0128 | -0.0128 | 0.0066 | -0.0124 | 2.41 | 0.9412 | 37.28 | 167,750.00 | -410.43 | -463.75 | -- | -- | 88.08 | -- | -170.04 | -732.15 | 0.0194 | -- | -- | -- | -- | -- | -854.23 | -- | -- | -- |
| Cannapharmarx Inc | 0.00 | -7.50m | 3.38m | 6.00 | -- | -- | -- | -- | -0.0274 | -0.0274 | 0.00 | -0.0715 | 0.00 | -- | -- | 0.00 | -141.75 | -161.34 | -- | -- | -- | -- | -- | -- | -- | -3.49 | -- | -- | -- | -- | 3.41 | -- | -- | -- |
| ENDRA Life Sciences Inc | 0.00 | -10.06m | 3.39m | 21.00 | -- | 0.5639 | -- | -- | -1.93 | -1.93 | 0.00 | 0.5447 | 0.00 | -- | -- | 0.00 | -125.53 | -132.00 | -149.91 | -157.28 | -- | -- | -- | -- | -- | -- | 0.005 | -- | -- | -- | 23.67 | -- | -19.46 | -- |
| Zyversa Therapeutics Inc | 0.00 | -106.25m | 3.41m | 7.00 | -- | 0.1642 | -- | -- | -1,922.89 | -1,922.89 | 0.00 | 27.33 | 0.00 | -- | -- | 0.00 | -139.81 | -- | -160.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -340.15 | -- | -- | -- |
| Onconetix Inc | 58.47k | -37.41m | 3.48m | 12.00 | -- | -- | -- | 59.57 | -2.09 | -2.09 | 0.0034 | 2.63 | 0.001 | -- | 0.6301 | 4,872.50 | -65.73 | -- | -87.29 | -- | -1,927.76 | -- | -63,981.00 | -- | 0.3185 | -19.88 | 0.1292 | -- | -- | -- | -176.78 | -- | -- | -- |
| Altamira Therapeutics Ltd | 0.00 | -8.00m | 3.49m | 10.00 | -- | 0.3244 | -- | -- | -16.28 | -8.67 | 0.00 | 4.81 | 0.00 | 34.05 | 32.30 | 0.00 | -103.88 | -73.80 | -6,364.67 | -123.19 | -87.90 | -- | -- | -- | 1.38 | -4.37 | 0.0152 | -- | -- | -- | 61.02 | -- | -- | -- |
| Bon Natural Life Ltd | 29.52m | 4.60m | 3.53m | 96.00 | 0.5070 | 0.0837 | 0.6403 | 0.1195 | 4.99 | 4.99 | 32.10 | 30.23 | 0.7045 | 15.27 | 5.19 | 307,524.60 | 10.86 | 14.04 | 13.69 | 20.68 | 29.94 | 30.00 | 15.42 | 17.62 | 2.41 | 30.54 | 0.0955 | 0.00 | -1.29 | 22.32 | -26.32 | 83.09 | -6.70 | -- |
| Bio Path Holdings Inc | 0.00 | -13.96m | 3.54m | 10.00 | -- | -- | -- | -- | -27.39 | -27.39 | 0.00 | -3.48 | 0.00 | -- | -- | 0.00 | -216.97 | -70.80 | -390.65 | -76.87 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -15.94 | -- | -- | -- |
| Phio Pharmaceuticals Corp | 0.00 | -9.38m | 3.61m | 8.00 | -- | 0.6448 | -- | -- | -3.71 | -3.71 | 0.00 | 1.22 | 0.00 | -- | -- | 0.00 | -113.26 | -71.92 | -145.23 | -84.15 | -- | -- | -- | -253,785.70 | -- | -- | 0.00 | -- | -- | -- | 5.70 | -- | 0.00 | -- |
| Atreca Inc | 0.00 | -97.76m | 3.65m | 90.00 | -- | 0.3388 | -- | -- | -2.49 | -2.49 | 0.00 | 0.2715 | 0.00 | -- | -- | 0.00 | -98.54 | -44.99 | -116.19 | -48.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 11.13 | -- | -8.46 | -- |
| Sonoma Pharmaceuticals Inc | 12.31m | -5.08m | 3.68m | 9.00 | -- | 0.4826 | -- | 0.2992 | -0.9608 | -0.9608 | 1.95 | 0.489 | 0.8625 | 2.58 | 4.76 | 1,367,778.00 | -35.56 | -37.52 | -47.14 | -51.35 | 39.17 | 40.17 | -41.23 | -37.12 | 3.11 | -- | 0.0065 | -- | 5.10 | -4.44 | -1.28 | -- | 7.54 | -- |
| Holder | Shares | % Held |
|---|---|---|
| UBS Securities LLCas of 31 Dec 2023 | 6.81k | 0.43% |
| Tower Research Capital LLCas of 31 Dec 2023 | 851.00 | 0.05% |
| Group One Trading LPas of 31 Mar 2024 | 14.00 | 0.00% |
| Citadel Securities LLCas of 31 Dec 2023 | 0.00 | 0.00% |
| Wells Fargo Clearing Services LLCas of 31 Mar 2024 | 0.00 | 0.00% |
| Armistice Capital LLCas of 31 Dec 2023 | 0.00 | 0.00% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2023 | 0.00 | 0.00% |
| XTX Markets LLCas of 31 Dec 2023 | 0.00 | 0.00% |
